To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops, but may also be given systemically as tablets or injections.
Additional recommended knowledge
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. Fusidic acid is only effective on gram-positive bacteria such as Staphylococcus species and Corynebacterium species. Fusidic acid inhibits bacterial replication and does not kill the bacteria, and is therefore termed "bacteriostatic".
Fusidic acid is a true antibiotic, derived from the fungus Fusidium coccineum and was developed by Leo Laboratories in Ballerup, Denmark and released for clinical use in the 1960s. It has also been isolated from Mucor ramannianus and Isaria kogana. The drug is not licensed for use in the US, but, as sodium fusidate, it is approved for use under prescription in the UK, Canada, Europe, Australia and New Zealand.
Fusidic acid is active in vitro against Staphylococcus aureus, most coagulase-negative staphylococci, Corynebacterium species, most clostridium species. Fusidic acid has no useful activity against streptococci, enterococci or most Gram-negative bacteria (except Neisseria, Moraxella, Legionella pneumophila and Bacteroides fragilis). Fusidic acid is active in vitro and clinically against Mycobacterium leprae but has only marginal activity against Mycobacterium tuberculosis.
The most important use of fusidic acid clinically is its activity against Methicillin Resistant Staphylococcus Aureus, a sometimes-fatal 'hospital-acquired 'superbug'. Many strains of MRSA remain sensitive to fusidic acid, but because there is a low genetic barrier to resistance (a single point mutation is all that is required), fusidic acid must never be used on its own to treat MRSA and should be combined with another antimicrobial such as rifampicin.
Fusidic acid is often found in topical skin and eye preparations (e.g., Fusibet®), a use which has been contested.
Fusidic acid should not be used on its own to treat Staph. aureus infections. The use of topical preparations (skin creams and eye ointments) containing fusidic acid is strongly associated with the development of resistance, and there are voicing agitating against the continued use of fusidic acid monotherapy in the community. Topical preparations used in Europe often contain fusidic acid and gentamicin in combination, which helps to prevent the development of resistance.
Depending on the reason for which sodium fusidate is prescribed the adult dose can be 250 mg twice a day and or up to 750 mg three times a day. (Skin conditions normally need the smaller dose). It is available in tablet and suspension form. There is an intravenous preparation available but it is irritant to veins, causing phlebitis. Most people absorb the drug extremely well after taking it orally so, if a patient can swallow, there is not much need to administer it intravenously, including endocarditis (infection of the heart chambers).
'There is inadequate evidence of safety in human pregnancy. Animal studies and many years of clinical experience suggest that fusidic acid is devoid of teratogenic effects (birth defects)...fusidic acid can cross the placental barrier.
Because the drug is not licensed for use in the US, and there are therefore no Clinical and Laboratory Standards Institute standard definitions of fusidic acid resistance.
In the UK and Australia, susceptibility is defined as an minimum inhibitory concentration (MIC) of 0.25mg/l or 0.5mg/l or less. Resistance is defined as an MIC of 2mg/l or more. In laboratories using disc diffusion methods, susceptibility for a 2.5µg disc is defined as a zone of 22 mm or more, and resistance is defined as a zone of 17 mm or less; intermediate values are defined as intermediate resistance.
Mechanisms of resistance have only been extensively studied in Staphylococcus aureus. The most important mechanism is the development of point mutations in fusA, the chromosomal gene which codes for EF-G. The mutation alters EF-G so that fusidic acid is no longer able to bind to it. Resistance is readily acquired when fusidic acid is used alone and commonly develops during the course of treatment, but resistance does not occur when fusidic acid is used in combination with other antibiotics. For this reason, fusidic acid should not be used on its own to treat Staph. aureus infections.
Some bacteria also mediate resistance via the fusB gene, which is carried on a plasmid; the mechanism by which fusB causes resistance is unknown.
Fusidic acid must not be used with quinolones, with which they are antagonistic. When combined with rifampicin, the action of fusidic acid is additive or synergistic.
It is delivered as an ointment, a cream, eye drops or in tablet form.
Trade names and preparations
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Fusidic_acid". A list of authors is available in Wikipedia.|